erlotinib hydrochloride has been researched along with debio 0932 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (debio 0932) | Trials (debio 0932) | Recent Studies (post-2010) (debio 0932) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 15 | 1 | 13 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | debio 0932 (IC50) |
|---|---|---|---|
| Heat shock protein HSP 90-alpha | Homo sapiens (human) | 0.033 | |
| Heat shock protein HSP 90-beta | Homo sapiens (human) | 0.038 | |
| Endoplasmin | Canis lupus familiaris (dog) | 0.19 | |
| Heat shock protein 75 kDa, mitochondrial | Homo sapiens (human) | 1.586 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Forrester, J; Lai, CJ; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
1 other study(ies) available for erlotinib hydrochloride and debio 0932
| Article | Year |
|---|---|
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |